BACKGROUND/OBJECTIVES: Cancer- or chemotherapy-related cognitive deficit is a common side effect occurring in patients with Hodgkin lymphoma. No previous study compared the influence of different types of treatment on the onset and development of chemotherapy cognitive impairment in longitudinal design. The aim of this study was to assess whether a more intensive form of chemotherapy causes greater cognitive impairment. METHODS: Forty-four patients at three different stages of the disease and with three different treatments (ABVD + 30 Gy, BEACOPPesc, or ABVD + 30 Gy plus BEACOPPesc) completed the neuropsychological battery and psychological measures of affective distress and quality of life. We compared their cognitive performance before, immediately after, and 6 months after the treatment. RESULTS: Whether or not we divided the total number of people with Hodgkin lymphoma into two groups (mild and moderate disease versus severe disease) or three groups (mild, moderate, and advanced disease), we found no statistically significant difference between the groups in cognitive performance or other psychological factors or experienced quality of life. CONCLUSIONS: Our results did not show that disease stage or treatment protocol had an effect on the depth of cognitive impairment in cancer or chemotherapy. We hypothesize that, in terms of brain health, intensive forms of chemotherapy (6 × BEA-COPPesc) do not pose a greater risk than milder forms (4 × ABVD + 30 Gy IF RT and 2 × BEACOPPesc + 4 × ABVD + 30 Gy IF RT) of cancer treatment for Hodgkin lymphoma. However, a limitation of our study is the small number of participants in the study, so it would be advisable to repeat the study on a larger sample of patients. Confirmation of our results could be beneficial in that neither patients nor physicians need to worry that intensive chemotherapy will worsen cognitive deficits.

1st Faculty of Medicine Charles University Kateřinská 1660 32 12108 Prague Czech Republic

3rd Faculty of Medicine Charles University Ruská 87 Prague 10 10100 Prague Czech Republic

Department of Clinical Hematology University Hospital Královské Vinohrady Šrobárova 50 10034 Prague Czech Republic

National Institute of Mental Health Topolová 748 25067 Klecany Czech Republic

Zobrazit více v PubMed

Juríčková V., Fayette D., Jonáš J., Fajnerová I., Kozák T., Horáček J. Pretreatment Cancer-Related Cognitive Impairment in Hodgkin Lymphoma Patients. Curr. Oncol. 2023;30:9028–9038. doi: 10.3390/curroncol30100652. PubMed DOI PMC

Fayette D., Juríčková V., Kozák T., Mociková H., Gaherová L., Fajnerová I., Horáček J. Cognitive impairment associated with Hodgkin’s lymphoma and chemotherapy. Neurosci. Lett. 2023;797:137082. doi: 10.1016/j.neulet.2023.137082. PubMed DOI

Krull K.R., Sabin N.D., Reddick W.E., Zhu L., Armstrong G.T., Green D.M., Arevalo A.R., Krasin M.J., Srivastava D.K., Robison L.L., et al. Neurocognitive function and CNS integrity in adult survivors of childhood Hodgkin lymphoma. J. Clin. Oncol. 2012;29:3618–3624. doi: 10.1200/JCO.2012.42.6841. PubMed DOI PMC

Trachtenberg E., Mashiach T., Hayun B.R., Tadmor T., Fisher T., Aharon-Peretz J., Dann E.J. Cognitive impairment in Hodgkin lymphoma survivors. Br. J. Haematol. 2018;182:670–678. doi: 10.1111/bjh.15448. PubMed DOI

Vinokurova E.G., Marchenko A.A., Khrushchev S.O., Olexenko L.V., Rupchev G.E., Vybornykh D.E., Moiseeva T.N. Cognitive impairments in patients with Hodgkin’s lymphoma. HemaSphere. 2018;2:22–23.

Magyari F., Ivanka T., Egerhazi A., Simon Z., Miltenyi Z., Kosa K., Illes A. Cognitive dysfunction after treatment for Hodgkin lymphoma. HemaSphere. 2018;2:22. doi: 10.1097/01.hs9.0000547903.93436.6d. DOI

Ansell S.M. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2018;93:704–715. doi: 10.1002/ajh.25071. PubMed DOI

Engert A. ABVD or BEACOPP for Advanced Hodgkin Lymphoma. JCO. 2016;34:1167–1169. doi: 10.1200/JCO.2015.64.8683. PubMed DOI

Viviani S., Zinzani P.L., Rambaldi A., Brusamolino E., Levis A., Bonfante V., Vitolo U., Pulsoni A., Liberati A.M., Specchia G., et al. ABVD versus BEACOPP for Hodgkin’s Lymphoma When High-Dose Salvage Is Planned. N. Engl. J. Med. 2011;365:203–212. doi: 10.1056/NEJMoa1100340. PubMed DOI

Merli F., Luminari S., Gobbi P.G., Cascavilla N., Mammi C., Ilariucci F., Stelitano C., Musso M., Baldini L., Galimberti S., et al. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients with Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. J. Clin. Oncol. 2016;34:1175–1181. doi: 10.1200/JCO.2015.62.4817. PubMed DOI

Skoetz N., Will A., Monsef I., Brillant C., Engert A., von Tresckow B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavorable or advanced stage Hodgkin lymphoma. Cochrane Database Syst. Rev. 2017;5:CD007941. doi: 10.1002/14651858.CD007941.pub3. PubMed DOI PMC

Skurlova M., Holubova K., Kleteckova L., Kozak T., Kubova H., Horacek J., Vales K. Chemobrain in blood cancers: How chemotherapeutics interfere with the brain’s structure and functionality, immune system, and metabolic functions. Med. Res. Rev. 2024;44:5–22. doi: 10.1002/med.21977. PubMed DOI

Preiss M. Neuropsychologická Baterie Psychiatrického Centra Praha: Klinické Vyšetření Základních Kognitivních Funkcí. 3rd ed. Psychiatrické Centrum Praha; Praha, Czech Republic: 2012. p. 158.

Conners C.K. Conners Continuous Performance Test (Conners CPT 3™) & Conners Continuous Auditory Test of Attention (Conners CATA™) 3rd ed. Multi-Health Systems Inc.; Toronto, ON, Canada: 2015.

Černochová D., Goldmann P., Král P., Soukupová T., Šnorek V., Havlůj V. Hogrege-Testcentrum; Praha, Czech Republic: 2010. Wechslerova Inteligenční Škála pro Dospělé.

Krivá L’. Stroopův Test. Hogrefe-Testcentrum; Praha, Czech Republic: 2013.

Loring W., Meador K.J. The Medical College of Georgia (MCG) Complex Figures. In: Knight J.A., Kaplan E., editors. The Handbook of Rey-Osterrieth Complex Figure Usage: Clinical and Research Applications. Psychological Assessment Resources, Inc.; Odessa, FL, USA: 1989. pp. 313–321.

Øvlisen A.K., Jakobsen L.H., Kragholm K.H., Nielsen R.E., Hutchings M., Dahl-Sørensen R.B., Frederiksen H., Stoltenberg D., Bøgsted M., Østgård L.S.G., et al. Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients. Cancer Med. 2020;9:4395–4404. doi: 10.1002/cam4.2981. PubMed DOI PMC

Mitchell A.J., Chan M., Bhatti H., Haltom M., Grassi L., Johansen C., Meader N. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160–174. doi: 10.1016/S1470-2045(11)70002-X. PubMed DOI

Hinz A., Krauss O., Hauss J.P., Höckel M., Kortmann R.D., Stolzenburg J.U., Schwarz R. Anxiety and depression in cancer patients compared with the general population. Eur. J. Cancer Care. 2010;19:522–529. doi: 10.1111/j.1365-2354.2009.01088.x. PubMed DOI

Linendoll N., Saunders T., Burns R., Nyce J.D., Wendell K.B., Evens A.M., Parsons S.K. Health-related quality of life in Hodgkin lymphoma: A systematic review. HRQOL. 2016;14:114. doi: 10.1186/s12955-016-0515-6. PubMed DOI PMC

Kreissl S., Müller H., Goergen H., Meissner J., Topp M., Sökler M., Markova J., Bernhard J., Greil R., von Tresckow B., et al. Health-Related Quality of Life in Patients with Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. J. Clin. Oncol. 2020;38:2839–2848. doi: 10.1200/JCO.19.03160. PubMed DOI

Airaksinen E., Larssin M., Lundberg I., Forsell Y. Kognitivní funkce u depresivních poruch: Důkazy z populační studie. Psychol. Med. 2004;34:83–91. doi: 10.1017/S0033291703008559. PubMed DOI

Salthouse T.A. How general are the effects of trait anxiety and depressive symptoms on cognitive functioning? Emotion. 2012;12:1075. doi: 10.1037/a0025615. PubMed DOI PMC

Ptáček J., Raboch J., Vnuková J., Hlinka J., Červenková M. Standardization of Czech version of Beck depression inventory (BDI-II) Eur. Psychiatry. 2017;41:S539. doi: 10.1016/j.eurpsy.2017.01.744. DOI

Kamaradova D., Prasko J., Latalova K., Panackova L., Svancara J., Grambal A., Sigmundova Z., Ociskova M., Bares V., Cakirpaloglu S., et al. Psychometric properties of the Czech version of the Beck Anxiety Inventory–comparison between diagnostic groups. Neuroendocrinol. Lett. 2015;36:706–712. PubMed

Hamilton M. Hamilton depression rating scale (HAM-D) J. Neurol. Neurosurg. Psychiatry. 1960;23:56–62. doi: 10.1136/jnnp.23.1.56. PubMed DOI PMC

Hamilton M. The assessment of anxiety states by rating. Br. J. Health Psychol. 1959;32:50–55. doi: 10.1111/j.2044-8341.1959.tb00467.x. PubMed DOI

Dragomirecka E. Czech version of the World Health Organization Quality of Life (WHOQOL)–Translation and designing the response scales. Psychiatrie. 2006;10:68–73.

Baudino B., D’agata F., Caroppo P., Castellano G., Cauda S., Manfredi M., Geda E., Castelli L., Mortara P., Orsi L., et al. The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q. J. Nucl. Med. Mol. Imaging. 2012;56:559–568. PubMed

Magyari F., Virga I., Simon Z., Miltényi Z., Illés A., Kósa K., Ivánka T., Berecz R., Égerházi A., Illés Á. Assessment of cognitive function in long-term Hodgkin lymphoma survivors, results based on data from a major treatment center in Hungary. Support. Care Cancer. 2022;30:5249–5258. doi: 10.1007/s00520-022-06918-6. PubMed DOI PMC